Harvest Portfolios Group Inc. Sells 25,799 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Harvest Portfolios Group Inc. reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 24.0% in the 4th quarter, HoldingsChannel.com reports. The firm owned 81,748 shares of the biopharmaceutical company’s stock after selling 25,799 shares during the quarter. Regeneron Pharmaceuticals makes up about 1.1% of Harvest Portfolios Group Inc.’s portfolio, making the stock its 27th largest position. Harvest Portfolios Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $63,099,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. TD Private Client Wealth LLC raised its holdings in Regeneron Pharmaceuticals by 9.7% during the 4th quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 15 shares during the last quarter. Meyer Handelman Co. raised its holdings in Regeneron Pharmaceuticals by 0.6% during the 4th quarter. Meyer Handelman Co. now owns 2,878 shares of the biopharmaceutical company’s stock worth $2,221,000 after purchasing an additional 18 shares during the last quarter. Gateway Investment Advisers LLC raised its holdings in Regeneron Pharmaceuticals by 4.3% during the 4th quarter. Gateway Investment Advisers LLC now owns 464 shares of the biopharmaceutical company’s stock worth $358,000 after purchasing an additional 19 shares during the last quarter. MGO One Seven LLC raised its holdings in Regeneron Pharmaceuticals by 3.3% during the 4th quarter. MGO One Seven LLC now owns 589 shares of the biopharmaceutical company’s stock worth $455,000 after purchasing an additional 19 shares during the last quarter. Finally, Whittier Trust Co. raised its holdings in Regeneron Pharmaceuticals by 5.9% during the 4th quarter. Whittier Trust Co. now owns 357 shares of the biopharmaceutical company’s stock worth $277,000 after purchasing an additional 20 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron announced a strategic collaboration with Parabilis Medicines to develop novel Antibody-Helicon Conjugates across multiple therapeutic areas, a deal that could be worth up to about $2.2 billion in milestone payments plus royalties and expands REGN’s pipeline into “undruggable” targets. Article: Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
• Positive Sentiment: Several analysts still maintained constructive views on REGN despite trimming price targets, including buy/overweight calls from firms such as Canaccord, JPMorgan, Piper Sandler, BMO, and Wells Fargo, suggesting Wall Street still sees meaningful upside from current levels.
• Neutral Sentiment: Regeneron’s latest earnings backdrop remains solid, with Q1 revenue up 19% year over year and results that beat consensus estimates, helping offset some of the pressure from recent headlines.
• Negative Sentiment: The main driver of the stock’s weakness was a late-stage melanoma trial failure: fianlimab plus cemiplimab did not meet its primary progression-free survival endpoint versus Merck’s Keytruda, raising questions about the company’s near-term oncology growth prospects. Article: Regeneron drops after skin cancer treatment misses late-stage trial goal
• Negative Sentiment: The trial miss triggered multiple analyst price-target cuts and a wave of shareholder-investigation headlines, adding to sentiment pressure and keeping attention on execution risk in REGN’s pipeline.

Regeneron Pharmaceuticals Stock Up 0.1%

Regeneron Pharmaceuticals stock opened at $630.30 on Wednesday. The company’s 50 day simple moving average is $739.39 and its 200 day simple moving average is $745.76. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The firm has a market capitalization of $66.64 billion, a price-to-earnings ratio of 15.36, a PEG ratio of 1.40 and a beta of 0.30. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. During the same quarter last year, the firm earned $8.22 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 19.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.1 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th will be paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the transaction, the director directly owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. The trade was a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 1,638 shares of the business’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. The trade was a 49.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 6.97% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

REGN has been the subject of several recent research reports. Guggenheim boosted their price objective on Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a “buy” rating in a report on Friday, May 1st. Canaccord Genuity Group cut their price target on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research note on Tuesday. Leerink Partners reissued a “market perform” rating and issued a $641.00 price target (down from $792.00) on shares of Regeneron Pharmaceuticals in a research note on Monday. Truist Financial cut their price target on Regeneron Pharmaceuticals from $796.00 to $778.00 and set a “buy” rating on the stock in a research note on Monday. Finally, Oppenheimer reissued an “outperform” rating and issued a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $792.65.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.